Back to Stakeholders

Enterprise Intelligence

Quarterly psychedelic drug-development briefing

Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.

Browse briefingsOpen Q2 briefing

Eywa Biotech is a Uruguayan synthetic-biology company, founded in Montevideo in 2022 by Paola Rodríguez Camarot and Victoria Costa Paz, that uses metabolic engineering and fermentation to produce GMP-grade psychedelic active pharmaceutical ingredients, including psilocybin, DMT, 5-MeO-DMT and bufotenin. It aims to provide a sustainable, high-purity supply chain for psychedelic compounds used in research and therapeutics, and raised a US$2.5 million round led by Tim Draper.

Manufacturing Snapshot

Psychedelic-Focused Manufacturer

Scope & Capabilities

API ProductionDrug Product Manufacturing

Supply Use Cases

Research UseClinical TrialsCommercial / Licensed Supply

GxP / Compliance

General GxP

Facilities & Access

Eywa positions its platform around biosynthesis of clinical-grade APIs and finished drug products for global research and clinical use.

Manufacturing Details

Supported Substances

Eywa lists clinical-grade psychedelic compounds and compounds portfolio entries for psilocybin, DMT, 5-MeO-DMT, and bufotenine.

Manufacturing Sources

Eywa Home

https://www.eywa.bio/

Eywa About Us

https://www.eywa.bio/aboutus

Quick Facts

Founded
2022
HQ
Uruguay
Website
Visit